A Phase II, randomized, double-blind, placebo-controlled repeated-dose study to evaluate the efficacy, safety, tolerability, and PK/PD of intravenously administered MOR106 in adult subjects with moderate to severe atopic dermatitis
Phase of Trial: Phase II
Latest Information Update: 17 Aug 2018
At a glance
- Drugs MOR 106 (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Acronyms IGUANA
- Sponsors Galapagos NV
- 19 Jul 2018 According to a MorphoSys media release, MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner,Upon the signing of the agreement, all future research, development, manufacturing and commercialization costs for MOR106 will be borne by Novartis.
- 01 May 2018 Status changed from planning to recruiting, according to a MorphoSys media release.
- 01 May 2018 According to a MorphoSys media release, first patient has been screened in this trial.